Login to Your Account



RNAi Patent Debate' Due Later?

Novartis Tapping Alnylam; Sirna 'Sticks To Strategy'

By Randall Osborne


Monday, September 12, 2005

"We think, unquestionably, we're the leaders," said Van Miles, senior vice president of business development for Alnylam Pharmaceuticals Inc., talking last week about RNA interference.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription